Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B (Epi_GDM_B)
This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.
The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Maternal metabolism during pregnancy plays an important role in fetal development and may influence the establishment and development of epigenetic signatures in the fetus. Epigenetic modifications, such as DNA methylation, regulate gene expression and are involved in numerous developmental processes. Alterations in these epigenetic patterns during pregnancy may have long-term consequences for offspring health and susceptibility to metabolic diseases. In particular, maternal metabolic conditions, including gestational diabetes mellitus (GDM), may influence fetal epigenetic programming. However, the dynamic development of fetal epigenetic signatures throughout pregnancy and their relationship with maternal metabolic changes remain insufficiently understood.
Investigating the fetal epigenome during pregnancy has long been challenging due to the limited availability of fetal tissue and the risks associated with invasive sampling procedures. The discovery of fetal cell-free DNA (cfDNA) circulating in maternal blood provides a non-invasive opportunity to investigate fetal characteristics during pregnancy. Recent advances in cell-free DNA analysis have made it possible not only to detect fetal genetic information but also to characterize fetal epigenetic signatures.
The primary objective of this study is to investigate the development and changes in fetal epigenetic signatures throughout pregnancy and to assess how maternal metabolic profiles influence these signatures. In particular, the study aims to identify associations between maternal metabolic parameters and fetal epigenetic modifications and to explore potential changes in these associations over the course of pregnancy. Furthermore, the study seeks to identify fetal epigenetic signatures associated with [specific maternal metabolic conditions, e.g. gestational diabetes mellitus] and to explore their potential as biomarkers of maternal metabolic status and fetal development.
To address these objectives, maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples collected at 11+0-13+6, 19+0-24+0, and 28+0-34+0. Fetal health will be assessed via ultrasound measures at these timepoints. Maternal glucose metabolism will be characterized using an oral glucose tolerance test (OGTT) at 24+0-27+6. Fetal epigenetic signatures will be investigated by analyzing fetal cell-free DNA circulating in maternal blood samples collected at all four timepoints.
By combining longitudinal maternal metabolic assessments with the analysis of fetal epigenetic signatures, this study aims to provide new insights into the relationship between maternal metabolism and fetal epigenetic development during pregnancy. The findings may contribute to a better understanding of the mechanisms underlying fetal metabolic programming and the potential long-term consequences of altered maternal metabolism for offspring health.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Martin Heni, Prof. MD
- Telefonnummer: +49 731 500 44505
- E-Mail: martin.heni@uniklinik-ulm.de
Studieren Sie die Kontaktsicherung
- Name: Sabrina Wangler, M.Sc.
- Telefonnummer: +49 731 500 44782
- E-Mail: sabrina.wangler@uniklinik-ulm.de
Studienorte
-
-
-
Ulm, Deutschland, 89081
- Ulm University Hospital
-
Kontakt:
- Sabrina Wangler, M.Sc.
- Telefonnummer: +49 731 500 44782
- E-Mail: sabrina.wangler@uniklinik-ulm.de
-
Kontakt:
- Martin Heni, Prof. MD.
- Telefonnummer: +49 731 500 44505
- E-Mail: martin.heni@uniklinik-ulm.de
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Participants will be recruited from public advertisements posted at Ulm University as well as through cooperations with local gynecologists.
Beschreibung
Inclusion Criteria:
- Pregnant women from gestational week 13+0
- No known underlying medical conditions i
- No known underlying diseases
- Understanding and voluntary signing of a consent form before study- related examinations
Exclusion Criteria:
- Age < 18 years
- Type 1 or type 2 diabetes mellitus
- Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
- Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
- Current depression or other psychiatric disorders
- Eating disorders
- Regular use of medication during pregnancy
- Pre-existing cardiovascular disease
- Drug and/or alcohol abuse
- Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
- C-reactive protein > 10 mg/l
- Transaminase elevation of 2 times the upper norm
- No consent to be informed about incidentally discovered pathological findings
- Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: FAMILY_BASED
- Zeitperspektiven: PROSPECTIVE
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Pregnant women
Metabolic and epigenetic characterization |
Maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples and at an additional time point using an oral glucose tolerance test (OGTT). Fetal epigenetic signatures will be investigated through the analysis of fetal cell-free DNA circulating in maternal blood. Fetal health will be assessed by ultrasound at the timepoints of the fasting blood samples No therapeutic intervention will be performed. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Epigenetic profiles of mothers and fetuses
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Methylation pattern of CpG sites in fathers, mothers and fetuses assessed from blood samples from the father and the mother. Genome-wide DNA methylation will be quantified as 5-methylcytosine (5mC) levels at CpG sites in maternal and paternal nuclear DNA from peripheral blood. Long-read sequencing will be used to detect genomic sequences and base modifications. Fetal DNA methylation will be assessed from fetal cell-free DNA isolated from maternal plasma using long-read sequencing. Allelic phasing will be applied to assign epigenetic modifications to parental origin. Deconvolution analysis will be used to subtract blood cell-derived epigenetic patterns and infer tissue-of-origin signals. |
Gestational weeks 13+0 - 34+0
|
|
Changes in epigenetic profiles of mothers and fetuses during pregnancy
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Changes in epigenetic profiles as determined in Primary Outcome 1 during pregnancy. |
Gestational weeks 13+0 - 34+0
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Epigenetic signatures of gestational diabetes
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Differentially methylated regions will be computed across parental genomic DNA and fetal cell-free DNA between women with and without gestational diabetes. Differentially methylated regions will be bioinformatically annotated to candidate genes and pathogenic pathways. |
Gestational weeks 13+0 - 34+0
|
|
Correlation of epigenetic signatures and glycemia
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Glucose level assessed from glucose measurements from fasting blood sample or oral glucose tolerance test. |
Gestational weeks 13+0 - 34+0
|
|
Correlation of epigenetic signatures with weight gain
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Correlation of changes in epigenetic signatures as assessed in primary outcome 2 with maternal weight gain. |
Gestational weeks 13+0 - 34+0
|
|
Correlation of epigenetic signatures and insulin sensitivity
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Insulin sensitivity assessed by Homeostasis Model Assessment of insulin resistance based on glucose and insulin measurements from fasting blood sample or oral glucose tolerance test. |
Gestational weeks 13+0 - 34+0
|
|
Correlation of epigenetic signatures and insulin secretion
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Insulin secretion assessed by Homeostasis Model Assessment of beta-cell function based on glucose and insulin measurements from fasting blood sample and oral glucose tolerance test. |
Gestational weeks 13+0 - 34+0
|
|
Correlation of epigenetic signatures and lipids
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Lipid profiles assessed from lipid measurements from fasting blood sample. |
Gestational weeks 13+0 - 34+0
|
|
Correlation of of epigenetic signatures with anthropometric features of the fetus
Zeitfenster: Gestational weeks 13+0 - 34+0
|
Correlation of epigenetic signatures as assessed by primary outcome 1 with anthropometric features of the features assessed by ultrasound. |
Gestational weeks 13+0 - 34+0
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Erkrankungen des endokrinen Systems
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Stoffwechselerkrankungen
- Schwangerschaftskomplikationen
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Ernährungs- und Stoffwechselerkrankungen
- Schwangerschaftsdiabetes
- Therapeutika
- Patientenversorgung
- Gesundheitsdienste
- Belegschaft und Dienstleistungen für Gesundheitseinrichtungen
- Community Health Services
- Stoffwechsel
- Mütterliche Gesundheitsdienste
- Stoffwechseletzwerke und Wege
- Vorgeburtliche Pflege
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 28/25 Amendment
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .